Price (delayed)
$6.105
Market cap
$486.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.76
Enterprise value
$898.57M
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings
There are no recent dividends present for CHRS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.